Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to InvestingPro data, the stock currently trades at $6.40, with analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback